The FDA narrowed the indications for pembrolizumab (Keytruda) and nivolumab (Opdivo) in gastric, gastroesophageal junction ...

Positive new data suggests that more people facing advanced breast cancer may be able to put off treatment with harsh ...

Among patients with HR+/HER2+ breast cancer, Herceptin and Perjeta plus endocrine therapy proved to be beneficial without chemotherapy. Treatment with Herceptin (trastuzumab) and Perjeta (pertuzumab) ...

Atezolizumab may improve upon perioperative treatment with trastuzumab and chemotherapy in HER2+, locally advanced, resectable gastric or GEJ cancer, researchers say.

AstraZeneca and Daiichi Sankyo’s drug extended survival by 30% compared to a widely used regimen, further establishing its ...

Study results unveiled at ASCO show combining Enhertu with Perjeta can significantly delay tumor growth versus a regimen that ...

Explore how cutting-edge agents like alpelisib, capivasertib, MEK and ERK inhibitors, and JAK inhibitors are reshaping the ...

Researchers at ASCO's annual meeting also discussed the importance of repeat biopsies to assess HER2 status after first-line ...

Trastuzumab deruxtecan plus pertuzumab demonstrated statistically and clinically significant improvement in progression-free ...

SHA-registered beneficiaries will now have full coverage for treatment cycles costing up to Sh700,000 annually.